Background: There is a paucity of studies describing trabecular bone score (TBS) and bone mineral density (BMD) in kidney transplant (KT) recipients from developing countries.
Study Setting: This prospective observational study, from a tertiary teaching hospital in India assessed clinical, biochemical parameters including bone turnover markers and dual-energy X-ray absorptiometry (DXA) for BMD/TBS, hip structural analysis (HSA) and vertebral fracture assessment (VFA) at pre-KT, 3 months and 12 months post-KT.
Results: A total of 53 KT recipients (90.6% living related) were recruited from August 2019 to March 2020 and followed till 1-year post-KT. The mean age was 33.9±10.4 years, 71.7% were males, and 11.5% had a history of pre-KT steroid use. Baseline fractures pre-KT as assessed by VFA were seen in 4 patients (7.5%). Mean BMD at spine and femoral neck and HSA variables at narrow neck and femoral shaft continued to decline till 3 months, but stabilised and reached pre-KT values 12 months post-KT. However, TBS and bone turn over markers continued to decline till 12 months post-KT (p value <0.001). New onset vertebral fractures were seen in 2(3.7%) and 1 patient (2.3%) at 3- and 12-months post-KT respectively. Pre-KT BMD significantly influenced bone health at 12 months post-KT, with patients in each quartile maintaining a similar trajectory over the follow up period (p < 0.001).
Conclusion: Despite significant improvement in kidney function following transplant, TBS and BMD of the spine significantly decreased mainly in the early post-KT period suggesting the effect of immunosuppressants on the bone. Strategies to improve bone health in KT patients are warranted.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jocd.2024.101534 | DOI Listing |
Ann Surg
March 2025
Health Care Delivery Research, Mayo Clinic Florida.
Objective: This study addressed whether kidney transplant (KTx) candidates, ages 60+, should accept a high KDPI kidney and differences when considering a high (>85% vs low (<85%) KDPI KTx.
Summary/background Data: To date, there is limited survival data to guide decision-making for patients aged 60 years and older who are faced with the choice of accepting a high KDPI kidney or remaining on the waitlist.
Methods: Propensity-matched cohort study using data from United Network on Organ Sharing (2014-2021).
R Soc Open Sci
March 2025
Interface Analysis Centre, HH Wills Physics Laboratory, School of Physics, University of Bristol, Bristol, UK.
Transplantation is the standard treatment for end-stage kidney disease but carries with it a non-trivial risk of post-operative complication. There is a need for a continuous, real-time, not additionally invasive method of monitoring organ perfusion. We present an approach to allograft perfusion monitoring using a human kidney model using normothermic perfusion (EVNP) and custom spectroscopic optical reflectance probes.
View Article and Find Full Text PDFTransplant Direct
April 2025
Department of Urology, Faculty of Medicine, Medical Centre, University of Freiburg, Freiburg, Germany.
Background: This monocentric, randomized controlled trial aims to compare the outcomes of kidney transplant recipients with magnetic double-J (DJ) stents versus conventional DJ stents. Specifically, we assessed stent-related symptoms, procedural difficulties, pain and duration of removal, and associated costs.
Methods: A total of 30 patients were randomly assigned to receive either a magnetic DJ (mDJ) stent or a conventional, standard DJ (sDJ) stent during kidney transplantation using the Lich-Gregoir technique.
Transpl Int
March 2025
Department of General Surgery, Demiroglu Bilim University and Group Florence Nightingale Hospital, Istanbul, Türkiye.
Kidney donation is a safe procedure for carefully screened donors. The growing shortage of organs and improved survival rates among recipients of living donor transplants have broadened the criteria for acceptable living donors, including older individuals and those with pre-existing health conditions. Consequently, ensuring both the short- and long-term safety of living donors is of paramount importance.
View Article and Find Full Text PDFCan J Hosp Pharm
March 2025
, BSP, PharmD, PhD, is with the College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan.
Background: Tacrolimus is the most common calcineurin inhibitor given to kidney and liver transplant recipients. Prolonged-release once-daily tacrolimus (LCPT) is the newest formulation of this drug, but prescribing practices for tacrolimus across Canada are unknown.
Objectives: To investigate the use of tacrolimus across Canada, by determining coverage for the drug, exploring prescribing practices and factors related to decision-making, and identifying management methods for patients with rapid metabolism of tacrolimus.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!